---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-001459"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2026-01-09T23:59:59+00:00"
generated_at: "2026-05-16T11:04:11.363976+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rhythm Pharma Q4 2025 IMCIVREE revenue ~$57M (+11% QoQ); FY2025 ~$194M (+50% YoY)

## Summary
- Q4 2025 net product revenue ~$57M, up 11% sequentially from Q3 2025.
- FY2025 net product revenue ~$194M, a ~50% increase from $130M in FY2024.
- U.S. sales contributed ~68% of Q4 and ~69% of full-year 2025 revenues.
- FDA PDUFA goal date of March 20, 2026 for setmelanotide sNDA in acquired hypothalamic obesity.
- Topline data from Phase 3 EMANATE trial in MC4R pathway diseases expected in Q1 2026.

## SEC filing metadata
- accession: 0001628280-26-001459
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2026-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000162828026001459/0001628280-26-001459-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000162828026001459/rytm-20260109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-001459
- JSON: https://secwatch.observer/filing/0001628280-26-001459.json
- Plain text: https://secwatch.observer/filing/0001628280-26-001459.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.